RxDoctor Payments Data

Clay Cockerell, MD

Dermatopathology · Dallas, TXNPI 1235119298

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Almirall LLC at 40.6% of the total. Among dermatopathology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,558in general payments, 2019–2025

Across 111 payments — averaging $356.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Almirall LLC$16K
  • Merck$10K
  • Stemline Therapeutics Inc.$4K
  • Blueprint Medicines Corporation$3K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$635
  • Arcutis Biotherapeutics, Inc.$548
  • plus $5K from 22 others

What the payments were for

  • Consulting fees$22,72057%
  • Speaking & faculty fees$7,99520%
  • Travel & lodging$1,6034%
  • Food & beverage$7,23918%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,558 in reported general payments places this provider in the 90th percentile of 54 dermatopathology providers in Texas.

See all dermatopathology providers in Texas

Medicare billing

Part B allowed, 2024
$73,897
Medicare patients
459
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spinosad13$36,984
Malathion13$18,408

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →